Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides

Autor: Sean Whittaker, Adam Lerner, Madeleine Duvic, Joel Waksman, Francine M. Foss
Rok vydání: 2016
Předmět:
0301 basic medicine
Oncology
Adult
Male
Cancer Research
medicine.medical_specialty
Pathology
Cutaneous T-cell lymphoma
Phases of clinical research
Kaplan-Meier Estimate
Romidepsin
03 medical and health sciences
Young Adult
0302 clinical medicine
CTCL
Mycosis Fungoides
Refractory
Recurrence
Internal medicine
hemic and lymphatic diseases
Depsipeptides
Medicine
Humans
Young adult
Aged
Aged
80 and over
Mycosis fungoides
Histone deacetylase inhibitor
Antibiotics
Antineoplastic
business.industry
Pruritus
Hematology
Middle Aged
medicine.disease
Folliculotropic Mycosis Fungoides
Lymphoma
Lymphoma
T-Cell
Cutaneous
Histone Deacetylase Inhibitors
030104 developmental biology
Treatment Outcome
Cutaneous tumors
Drug Resistance
Neoplasm
030220 oncology & carcinogenesis
Disease Progression
Female
business
medicine.drug
Zdroj: Clinical lymphoma, myelomaleukemia. 16(11)
ISSN: 2152-2669
Popis: Background Tumor stage and folliculotropic mycosis fungoides are uncommon subtypes of cutaneous T-cell lymphoma (CTCL) with an aggressive disease course. Romidepsin is a histone deacetylase inhibitor approved by the US Food and Drug Administration for patients with CTCL who have received ≥ 1 previous systemic therapy. In the present study, we examined the efficacy and safety of romidepsin in patients from the pivotal, single-arm, open-label, phase II study of relapsed or refractory CTCL with cutaneous tumors and/or folliculotropic disease involvement. Materials and Methods Patients with CTCL who had received ≥ 1 previous systemic therapy received romidepsin at 14 mg/m 2 on days 1, 8, and 15 of 28-day cycles. Responses were determined by a composite endpoint (assessments of the skin, blood, and lymph nodes). Patients with cutaneous tumors and/or folliculotropic disease involvement were identified by review of diagnosis and histology reports. Results The objective response rate to romidepsin was 45% in patients with cutaneous tumors (n = 20) and 60% in patients with folliculotropic disease involvement (n = 10). Conclusion Romidepsin is active in subtypes of CTCL with less favorable outcomes, such as tumor stage and folliculotropic mycosis fungoides.
Databáze: OpenAIRE
Externí odkaz: